211 related articles for article (PubMed ID: 27146577)
1. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
3. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
8. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
10. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
13. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
15. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae.
Théon AP; Pusterla N; Magdesian KG; Wilson WD
J Vet Intern Med; 2013; 27(5):1209-17. PubMed ID: 23889748
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
